Werewolf Therapeutics Inc. Common Stock (HOWL)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Werewolf Therapeutics as a speculative biotech, not a Graham-style bargain. It has 39 employees and is developing conditionally activated immune therapies through its PREDATOR platform, with WTX-124 as lead candidate. The filed record is a chain of losses: net loss of $37.4M in FY2023, $70.5M in FY2024, and $60.8M in FY2025. The quarter ended 2026-06-30 did report net income of $3.7M, or $0.08 per diluted share, after a $13.5M loss in the quarter ended 2026-03-31; filed revenue is n/a. That one profitable quarter may be encouraging, but it does not yet prove commercial durability. Trailing free cash flow is -$30.1M, and the FairStock FCF yield is -62.6% against the $48.2M market cap at the 2026-10-13 close, so cash burn is the central fact. The FairStock calculation shows D/E of 0.72, ROE of -119.86%, ROCE of -27.39%, and an Altman Z-score of -21.86, which signals financial distress under that model. Piotroski is 4/9. P/B is 2.91 and P/E is -1.36, both FairStock calculations tied to that close; with negative earnings, the P/E is not meaningful, and 2.91 times book is not a bargain for a cash-burning biotech. The Lynch category is none because it has lost money in each of the last four years. The investment case rests on pipeline data or partnership cash, not on present earnings. I see no margin of safety in these numbers, only optionality. If trials disappoint or financing dries up, dilution and impairment are real risks.

In plain English: Werewolf Therapeutics is a small biotech company trying to make medicines that help the immune system fight cancer. It has lost money for years and spends cash, although the latest quarter showed a small profit, and its filings show no revenue for that period. At about one dollar a share, the price does not look clearly cheap compared with the company's uneven profits and cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer